Skip to main content
OpenTrials
Completed

NCT Number: NCT07751393

Signal-Transducing Adaptor Proteins in Periodontal Disease

This study will look at certain proteins in the gums, saliva, and gum fluid of people with healthy gums, gingivitis (mild gum inflammation), or periodontitis (more severe gum disease). The proteins to be studied called STAP-1, STAP-2, STAT3, STAT5A, NLRP3, and CASP3, are known to be involved in inflammation and cell health in other diseases, but their role in gum disease is not well understood. Seventy-five healthy adults will be grouped by their gum health status. Samples of saliva and gum fluid will be collected and tested, and gum tissue samples will be collected from a subset of participants during routine dental treatment. Researchers will measure the levels of these proteins and look for patterns linking them to the severity of gum disease. The results are expected to show whether these proteins are found at different levels in people with periodontitis compared to those with healthy gums, suggesting they may play a role in how gum disease develops and progresses. This information may help researchers better understand the biological processes behind periodontal disease and could eventually contribute to new ways of detecting or treating it.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Kubra Aral , Phd Ext. 422 341 01 06 [email protected]

Malatya, 44100, Turkey (Türkiye)

About this study

Signal-transducing adaptor proteins (STAPs), particularly STAP-1 and STAP-2, are involved in intracellular signaling pathways that regulate cell growth, immune responses, and inflammatory processes, and have been implicated in the pathogenesis of several chronic inflammatory and malignant conditions. Their regulatory partners, STAT3 and STAT5A, are transcription factors known to modulate immune and inflammatory signaling, while NLRP3 (a key component of the inflammasome) and CASP3 (a central mediator of apoptosis) are closely linked to tissue destruction and programmed cell death in chronic inflammatory diseases. Although periodontal disease is fundamentally driven by a dysregulated host inflammatory and immune response to bacterial biofilm, the involvement of STAP-1, STAP-2, and their associated signaling molecules in this process has not previously been investigated. This study will enroll 75 systemically healthy adults, allocated into three groups of 25 participants each based on periodontal status: periodontally healthy, gingivitis, and periodontitis. Diagnosis and group allocation will be based on standard clinical periodontal parameters. From all 75 participants, gingival crevicular fluid (GCF) and unstimulated whole saliva samples will be collected. In addition, gingival tissue biopsies will be obtained from a subset of 60 systemically healthy participants (20 per group), collected during periodontal or extraction procedures that are independently clinically indicated. GCF and saliva samples will be analyzed for total levels of STAP-1, STAP-2, STAT3, STAT5A, NLRP3, and CASP3 using enzyme-linked immunosorbent assay (ELISA). Gingival tissue samples will be analyzed for relative gene expression of the same six molecules using real-time quantitative polymerase chain reaction (RT-qPCR). Clinical periodontal parameters (such as probing depth, clinical attachment level, bleeding on probing, and plaque index) will be recorded for all participants at the time of sampling. Statistical analyses will compare protein and gene expression levels across the three periodontal groups and will assess correlations among STAP-1, STAP-2, STAT3, STAT5A, NLRP3, and CASP3, as well as their relationships with clinical periodontal parameters, within GCF, saliva, and gingival tissue. The study aims to determine whether STAP family proteins and their related inflammatory/apoptotic signaling molecules are differentially expressed according to periodontal disease severity, and whether they may serve as biological indicators involved in the inflammatory and tissue-destructive processes underlying periodontitis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria

for the Healthy Control group were: presence of ≥ 20 teeth in the mouth, probing pocket depth (PPD) ≤ 3 mm, the percentage of bleeding sites for the whole mouth < 10%, and, on radiographic examination, a distance of ≤ 3 mm between the cemento-enamel junction and the alveolar bone crest in 95% of all teeth. Inclusion criteria for the Gingivitis group were: presence of ≥ 20 teeth in the mouth, PPD ≤ 3 mm, % of bleeding sites for the whole mouth ≥ 10%, and, on radiographic examination, a distance of ≤ 3 mm between the cemento-enamel junction and the alveolar bone crest in 95% of all teeth. Inclusion criteria for the Stage 3 Periodontitis group were: presence of ≥ 15 teeth in the mouth, more than 30% of teeth affected by periodontal disease, affected teeth exhibiting probing depths of 6 mm or more and clinical attachment loss (CAL) of ≥ 5 mm, vertical bone loss of 3 mm or more, class 2 or 3 furcation involvement, and radiographic evidence of alveolar bone loss extending to the middle third and beyond (33%) in the relevant teeth

Exclusion criteria

Exclusion criteria

for all groups were defined as: presence of any systemic disease, regular use of any medication, smoking, pregnancy or lactation, periodontal treatment within the last 6 months, antibiotic use within the last 6 months, and the presence of prosthetic restorations on the teeth to be sampled.

Treatment and study plan

Primary outcomes

  1. GCF, saliva and Gingival levels of STAP-1, STAP-2, STAT3, STAT5A, NLRP3 and CASP3

    Time frame: From may to December 2024

    Gene expression (RT-PCR, relative fold change via 2^-ΔΔCT method)levels of STAP-1, STAP-2, STAT3, STAT5A, NLRP3 and CASP3 were measured in gingiva of participants. Protein levels of STAP-1, STAP-2, STAT3, STAT5A, NLRP3 and CASP3 in GCF and saliva were measured by ELISA in study participants.

Sponsors and collaborators

Lead sponsor

Inonu University

Other

Registry information

Official study title

Investigation of the Role of Signal-Transducing Adaptor Proteins in Periodontal Disease

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Aug 7, 2026
Registry last updated
Aug 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.